Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tetsuya Mitsudomi

Showing results (111-120 of 336) with videos related to

Pageof 34
Sort By:
Lung Cancer (Amsterdam, Netherlands)|June 3, 2018
Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancerMakoto Nishio, Kazuhiko Nakagawa, Tetsuya Mitsudomi, et al.
The Annals of Thoracic Surgery|September 23, 2008
Subcategorization of resectable non-small cell lung cancer involving neighboring structuresNoriaki Sakakura, Shoichi Mori, Futoshi Ishiguro, et al.
Lung Cancer (Amsterdam, Netherlands)|April 10, 2012
Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogeneTakayuki Fukui, Yasushi Yatabe, Yoshihisa Kobayashi, et al.
Plos One|February 14, 2017
Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC statusKenichi Suda, Leslie Rozeboom, Hui Yu, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|July 24, 2003
Different risk relations with smoking for non-small-cell lung cancer: comparison of TP53 and TP73 genotypesAkio Hiraki, Keitari Matsuo, Nobuyuki Hamajima, et al.
Lung Cancer (Amsterdam, Netherlands)|December 30, 2015
Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancerKenichi Suda, Isao Murakami, Kazuko Sakai, et al.
General Thoracic and Cardiovascular Surgery|August 19, 2011
Molecular oncology of lung cancerShinichi Toyooka, Tetsuya Mitsudomi, Junichi Soh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2006
Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviorsToshiyuki Takeuchi, Shuta Tomida, Yasushi Yatabe, et al.
Lung Cancer (Amsterdam, Netherlands)|July 10, 2016
Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)Masaki Shimoji, Shigeki Shimizu, Katsuaki Sato, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2009
Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosisShuta Tomida, Toshiyuki Takeuchi, Yukako Shimada, et al.
Pageof 34

Showing results (111-120 of 336) with videos related to

Sort By:
Pageof 34
Lung Cancer (Amsterdam, Netherlands)|June 3, 2018
Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancerMakoto Nishio, Kazuhiko Nakagawa, Tetsuya Mitsudomi, et al.
The Annals of Thoracic Surgery|September 23, 2008
Subcategorization of resectable non-small cell lung cancer involving neighboring structuresNoriaki Sakakura, Shoichi Mori, Futoshi Ishiguro, et al.
Lung Cancer (Amsterdam, Netherlands)|April 10, 2012
Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogeneTakayuki Fukui, Yasushi Yatabe, Yoshihisa Kobayashi, et al.
Plos One|February 14, 2017
Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC statusKenichi Suda, Leslie Rozeboom, Hui Yu, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|July 24, 2003
Different risk relations with smoking for non-small-cell lung cancer: comparison of TP53 and TP73 genotypesAkio Hiraki, Keitari Matsuo, Nobuyuki Hamajima, et al.
Lung Cancer (Amsterdam, Netherlands)|December 30, 2015
Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancerKenichi Suda, Isao Murakami, Kazuko Sakai, et al.
General Thoracic and Cardiovascular Surgery|August 19, 2011
Molecular oncology of lung cancerShinichi Toyooka, Tetsuya Mitsudomi, Junichi Soh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2006
Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviorsToshiyuki Takeuchi, Shuta Tomida, Yasushi Yatabe, et al.
Lung Cancer (Amsterdam, Netherlands)|July 10, 2016
Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)Masaki Shimoji, Shigeki Shimizu, Katsuaki Sato, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2009
Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosisShuta Tomida, Toshiyuki Takeuchi, Yukako Shimada, et al.
Pageof 34